In recent years, the FDA has issued several warning letters to companies that market unapproved drugs containing cannabidiol (CBD). These products are not approved by the FDA for the diagnosis, cure, mitigation, treatment, or prevention of any disease. Therefore, it is important for consumers to be aware of the potential risks associated with these products. CBD is a medication used to control and treat seizure disorders, Lennox-Gastaut syndrome and Dravet syndrome.
This article provides an overview of the indications, action and contraindications of CBD as a valuable agent in the treatment and treatment of Lennox-Gastaut syndrome and Dravet syndrome. It also highlights the mechanism of action, the profile of adverse events and other key factors, such as ongoing research trials on the use of CBD. Reports and recommendations have led to a shift in public perception of CBD, resulting in a growing market for CBD products.
